ESMO: AstraZeneca proposes adding Lynparza to Imfinzi as endometrial cancer race heats up
Fierce Pharma
OCTOBER 21, 2023
After two immunotherapies demonstrated their power against endometrial cancer, AstraZeneca now suggests that adding Merck-partnered Lynparza to its Imfinzi may offer another option.
Let's personalize your content